What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Executive Summary
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
You may also be interested in...
Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets
Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.
Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
GSK CTO, Boehringer Exec On The Metaverse And Pharma’s Foot In The Door
Big pharma executives discuss the transformative potential of the metaverse in the life sciences segment and how things are shaping in the virtual world amid the hype. GSK’s senior VP and chief technology officer outlines to Scrip gains made deploying digital twins and bots.